Furthermore, MGA mutations were most frequently seen in lung cancer (LUAD, 69%), prostate cancer (TGCT seminoma, 46%), and HPV-negative head and neck cancer (TGCT seminoma, 46%). This evidence concerns the gene MGA and prostate carcinoma.